

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1449A/P/T/O

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/591,485
Filing Date	November 7, 2007
First Named Inventor	Jacob Waugh
Art Unit	1656
Examiner Name	Samuel W. Liu
Attorney Docket Number	13720-105074US1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. *	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures appear
		Number - Kind Code ¹ (if known)			
		6,447,787	09-10-2002	Gassner et al.	
		6,458,763	10-01-2002	Peterson et al.	
		6,627,632	09-30-2003	Parks et al.	
		6,888,311	02-10-2004	Hanin	
		6,855,688	02-15-2005	McKerracher	
		6,958,147	10-25-2005	Alitalo et al.	
		7,138,105	11-21-2006	Bolofin	
		2004/0265935	12-30-2004	Atassi	
		2004/0109871	06-10-2004	Pascual	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. *	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures appear	X ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		JP 63-287730 (Abstract Only)	11-24-1988	Nippon Shokubai Kagaku Kogyo Co. Ltd.		X
		JP 2002-524527 (English translation in counterpart WO 00/15245)	08-06-2002	Elian Pharmaceuticals, Inc.		X
		JP 11-60475 (English translation in counterpart US 2002/0150613)	03-02-1999	Verteq Inc.		X
		WO9611712	04/25/1996	California Institute Technology		
		WO 2004/006954	01-22-2004	Allergan		

Examiner
Signature

/Samuel Liu/

Date
Considered

07/30/2011

*EXAMINER: Initial X reference considered, whether or not stated in an information with 35 USC 802. "Cite the document if not in accordance and not pertinent." Include copy of this form with next communication to applicant. *APPLICANT: Complete citation designation (number, kind code). See Table Online at USPTO Patent Documents at www.uspto.gov or 35 USC 801.04. *EXAMINER: Check second column of document by the law firm name (USPTO Standard E1.3). For Japanese cited documents, the indication of the year of the filing of the document must precede the serial number of the patent document. *X² of document by the appropriate symbol(s) indicated in the document under 35 USC 802 Standard E1.36. *APPLICANT: To place a check mark (X) in the first column (translation is attached). *X² of this reference of information is reported by 11 CFR, 1.17 and 1.18. This information is required to update, or enter a check, by the public, which is the first by the USPTO to process an application. Confidentiality is provided by 35 USC 1.12 and 1.12 LPR 1.14. This reference is relevant to law firms to complete this form before beginning the review of the document, which is not to be filed. Information (USPTO, 1.12, Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1480, Alexandria, VA 22303-1480; USPTO, 1.12, Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1480, Alexandria, VA 22303-1480).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2	2
---	---

Application Number	10/591,485
Filing Date	November 7, 2007
First Named Inventor	Jacob Waugh
Art Unit	1656
Examiner Name	Samuel W. Liu
Affirmey Docket Number	13720-105074US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T *
		Futaki et al., "Internalization of Branched Arginine Peptides into Cells," 27[P1]-120, The Pharmaceutical Society of Japan, Abstract, 123(2), March 2003	x
		Futaki, "Intracellular Delivery of Biopolymers Using Membrane-Permeable Peptides," Membrane, 28(2), pp. 55-60, 2003	x
		Futaki et al., "Novel Method for Introducing Protein into Cells Using Arginine Peptides," 27[P1]-118, Institute for Chemical Research, 123(2), p. 26, March 2003	x
		Kim, et al. "Sequence Requirements for the Assembly of Simian Virus 40 T Antigen and the T-Antigen Origin Binding Domain on the Viral Core Origin of Replication", J. Virol., Sept. 1999, pp. 7543-7555	
		Nosh et al., "Protein Stability and Stabilization through Protein Engineering," 1991, chapter 7, pages 197-217	
		Park et al., "Mutational Analysis of a Human Immunodeficiency Virus Type 1 TAT Protein Transduction Domain Which is Required for Delivery of a Exogenous Protein into Mammalian Cells," Journal of General Virology, 83, pp. 1173-1181, 2002	
		Somerman et al., Human Bone Sialoprotein I and II Enhance Fibroblast Attachment in Vitro," Calcif. Tissue Intl., 43, pp. 50-53, 1988	
		Thomas E. Creighton, in his book, "Proteins: Structure and Molecular Properties," 1984, pages 314-315	
		Thomas E. Creighton, in his book, "Protein Structure: A practical Approach," 1989, pages 184-186	
		Umezawa et al., "Development of β -peptides Having Ability to Penetrate Cell Membrane," 27[P1]-133, Faculty of Pharmaceutical Sciences, Nagoya City University, 123(2), p. 29, March 2003	
		Communication Pursuant to Article 94(3) EPC issued for European Patent Appin. No. 05759520.9 dated October 1, 2010	
		Communication Pursuant to Article 94(3) EPC issued for European Patent Appin. No. 05724470.9 dated October 19, 2010	

Exercises

/Samuel Liu/

Date
Considered

07/30/2011

[illegible]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./